Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: Differences between tumours located in the transition zone and in the peripheral zone

European Urology

Volumn 41, Issue 1, 2002, Pages 40-46

  Erbersdobler, Andreas ^a   Fritz, Henning ^a   Schnöger, Silvia ^a   Graefen, Markus ^b   Hammerer, Peter ^b   Huland, Hartwig ^b   Henke, R Peter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Apoptosis; Proliferation; Prostatic neoplasms; Zonal location

Indexed keywords

PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM;

AGED; APOPTOSIS; CELL DIVISION; CULTURE TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036313566     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(01)00021-5     Document Type: Article

References (40)

1. Normal histology of the prostate
2. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread
3. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread
4. Frequency and clinical significance of transition zone cancer in prostate cancer screening
5. An analysis of 148 consecutive transition zone cancers: Clinical and histological characteristics
6. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate
7. Immunohistochemical detection of p53 protein in human prostatic cancer
8. Administration cooperative urological research group: Histological grading and clinical staging of prostate carcinoma
9. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
10. Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy
11. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy
12. Locally recurrent prostate tumours following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity
13. Cell proliferation, apoptosis, oncogene, and tumour suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer
14. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma
15. Assessment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery
16. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate
17. Large, organ confined, impalpable transition zone prostate cancer: Association with metastatic levels of prostate specific antigen
18. Zonal origin of prostatic adenocarcinoma: Are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland?
19. Some small prostate cancers are non-diploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features
20. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate
21. Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: A seven year follow-up
22. Allelic losses at 8p, 10q, 11p, 13q, 16q, 17p, and 18q in prostatic carcinomas: The impact of zonal location, Gleason grade, and tumour multifocality
23. Prognostic significance of bcl-2 in clinically localised prostate cancer
24. Bcl-2 oncoprotein positivity and high Mib-l (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma
25. Cell proliferation rate by Mib-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas
26. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer
27. Ki-67 expression in early prostate cancer and associated pathological lesions
28. Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma. Comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylin-eosin staining
29. Expression of bcl-2, bax, and p53 in high-grade prostatic intraepithelial neoplasia and localised prostate cancer: Relationship with apoptosis and proliferation
30. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer
31. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma ol the prostate
32. Basic concepts and potential significance in human cancer
33. 1 and bcl-2 expression
34. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy
35. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
36. Tumour angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
37. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate
38. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localised prostate cancer
39. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy
40. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers